Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Editas Medicine (EDIT) Misses Q4 EPS by 9c
February 22, 2023 6:16 AM ESTEditas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($0.88), $0.09 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $6.5 million versus the consensus estimate of $3.66 million.
For earnings history and earnings-related data on Editas Medicine (EDIT) click here.
... More